$41M Crypto Push: EV Maker Faraday Future Takes 55% Stake in Qualigen for Web3 Transformation

Faraday Future (FFAI) announced a $41 million strategic investment in Qualigen Therapeutics (QLGN), with FFAI contributing $30 million for a 55% ownership stake, to transform QLGN into a crypto/Web3 company rebranded as CXC10. This pivot establishes three growth engines for CXC10, including a C10 Treasury that has already achieved a 7% unrealized gain on its initial crypto asset allocation, signaling a significant diversification for FFAI. Concurrently, FFAI provided updates on its FX Super One MPV, detailing advanced features and projecting initial deliveries for November 2025.

Analysis

Faraday Future (FFAI) is executing a significant strategic diversification by investing $30 million for a 55% controlling stake in Qualigen Therapeutics (QLGN), which will pivot entirely into a crypto and Web3 business rebranded as CXC10. This move diverts substantial capital and management attention from FFAI's core, capital-intensive electric vehicle operations. The new entity, CXC10, is structured around three growth engines: a treasury function (C10 Treasury), an AI-driven trading platform (BesTrade DeAI Agent), and ecosystem tokens. Early results from the C10 Treasury show a 7% unrealized gain on a $10 million crypto allocation, offering a preliminary proof of concept. Governance will be tightly controlled by FFAI, which plans to appoint key management, including its Global President as Co-CEO of CXC10, and secure up to four of seven board seats. Simultaneously, FFAI reaffirmed its commitment to the EV sector by detailing its FX Super One MPV, with initial deliveries slated for November 2025. This dual-track strategy represents a high-risk endeavor, leveraging the public listing of QLGN to build a new venture in a volatile market while still navigating the challenges of vehicle production.

Key Decisions for Investors

• Investors in Faraday Future (FFAI) should assess the strategic rationale behind diverting $30 million and key executive resources to a high-risk crypto venture, weighing the potential for value creation against the increased risk and distraction from its core EV business.
• Qualigen Therapeutics (QLGN) shareholders must recognize their investment has fundamentally transformed from a therapeutics company into a crypto/Web3 startup controlled by FFAI, and they should re-evaluate their position based on their tolerance for the volatility and regulatory uncertainty of the digital asset market.
• Monitor FFAI's execution on both its EV and crypto fronts, particularly the FX Super One MPV delivery timeline and the performance of the C10 Treasury, as success or failure in one area will likely impact investor sentiment and capital allocation for the other.
• Consider the potential for conflicts of interest and diluted management focus arising from FFAI executives holding leadership roles in both the parent company and the new CXC10 entity.